USANA Health Sciences, Inc. — Form 10-Q Summary
Period clarification: The request identifies 2014 Q3, but the filing is for the quarter ended October 3, 2015, with comparisons to the quarter ended September 27, 2014. Amounts below are in U.S. dollars; financial statement amounts are in millions unless otherwise indicated.
Business context and reporting period
USANA develops and manufactures nutrition and personal-care products sold internationally through independent distributors and preferred customers. It reported approximately 405,000 active Associates and 89,000 active Preferred Customers at October 3, 2015. International sales represented 84.2% of nine-month revenue. The company reports one operating segment, with geographic detail for Asia Pacific and Americas and Europe.
Financial results and liquidity
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Net sales | $233.3 | $191.9 | $685.9 | $562.6 |
| Gross profit | $192.2 | $157.4 | $566.4 | $459.3 |
| Gross margin | 82.4% | 82.0% | 82.6% | 81.6% |
| Operating earnings | $38.0 | $29.3 | $106.5 | $83.5 |
| Net earnings | $25.6 | $19.5 | $70.7 | $55.3 |
| Diluted EPS | $1.92 | $1.47 | $5.35 | $3.96 |
| Operating cash flow | Not separately stated | Not separately stated | $74.5 | $67.4 |
- Q3 sales rose 21.5% and net earnings rose 31.3% year over year. Diluted EPS increased 30.6% for the quarter and 35.1% for the first nine months.
- For the first nine months, associate incentives were 44.4% of sales (43.1% prior year); selling, general and administrative expense was 22.6% (23.7%); and the effective tax rate was 34.0% (33.8%).
- Cash and cash equivalents were $174.2 at October 3, 2015, up from $111.1 at January 3, 2015. Net working capital was $155.4, compared with $82.2 at year-end 2014.
- There was no outstanding balance on the $75.0 Bank of America credit facility. Bank guarantees reduced available borrowing capacity by $4.3. The facility expires in April 2016; the company reported compliance with its covenants.
- Nine-month investing cash outflow was $17.9, including $16.5 of property and equipment purchases. Financing cash inflow was $9.7, comprising excess tax benefits from equity awards; no shares were repurchased during the period.
Material changes and business drivers
- Asia Pacific sales grew 29.1% in Q3; Greater China sales grew 45.5%. China represented $95.1 of quarterly sales, compared with $50.4 a year earlier. Active Associates worldwide increased 39.2% year over year, with Greater China Associates up 69.0%.
- Management attributed growth to customer expansion, market-specific promotions and incentives, and price adjustments. Currency movements reduced Q3 sales by $18.3 and nine-month sales by $37.1; reported sales growth excluding currency effects was 31.1% for Q3 and 28.5% for the nine-month period.
- Inventory increased to $61.6 from $45.2 at January 3, partly reflecting higher China demand and preparation for the new China production facility.
- Foreign currency translation produced a nine-month other comprehensive loss of $4.0, net of tax; accumulated other comprehensive income moved from $2.1 at year-end to a loss of $1.9.
Outlook, risks and unusual items
- Management expected associate incentives to remain 44.0%–44.5% of sales for fiscal 2015. It expected the China manufacturing facility to begin operating in early 2016; the anticipated project investment was $40.0, of which $22.3 had been incurred through Q3 2015.
- USANA planned to begin operations in Indonesia in Q4 2015 and intended to officially launch MySmart Foods in the first half of 2016. The filing provides no specific full-year revenue or earnings guidance.
- China growth included approximately $17.0 of incremental sales following announcement of 2015 price adjustments. Management also anticipated continued year-over-year declines in Hong Kong sales and Associates through the remainder of 2015.
- The company reclassified acquired BabyCare product formulas from indefinite-lived to an eight-year estimated useful life after a China product-approval process began. The asset was tested, with no impairment recorded; amortization will be recognized prospectively.
- Management said existing cash, expected operating cash flow and available credit should cover ordinary operating and capital needs for the foreseeable future. Key risks include dependence on Associates and network marketing, China expansion, regulation, foreign exchange, suppliers, competition, and litigation or regulatory outcomes.
- No contingency liability was accrued at October 3 because management considered none probable and estimable; some reasonably possible matters could not be estimated. Management did not expect these matters, individually or collectively, to materially adversely affect results, liquidity or financial condition.
- After quarter-end through November 10, USANA repurchased and retired 133,400 shares for $17.6 at an average $131.84 per share; $43.6 remained authorized for repurchases.
Important facts for investors to verify
- Confirm the intended reporting period: the supplied filing is Q3 2015, not Q3 2014.
- Assess whether growth, particularly in China, is sustainable given incentives, price-related purchasing, and expected Hong Kong declines.
- Monitor currency effects, inventory growth, associate incentive costs, and execution and spending for the China facility.
- Review the April 2016 credit-facility expiry, covenant requirements, and subsequent share repurchases.
- Track the effect of the BabyCare formula amortization and the potential outcomes of unaccrued legal or regulatory contingencies.